Reuters logo
BRIEF-Actinium announces receipt of positive scientific advice from EMA for Iomab-B
March 21, 2017 / 11:10 AM / in 8 months

BRIEF-Actinium announces receipt of positive scientific advice from EMA for Iomab-B

March 21 (Reuters) - Actinium Pharmaceuticals Inc:

* Actinium announces receipt of positive scientific advice from the European Medicines Agency for Iomab-B

* EMA guidance provides clear regulatory pathway for EU approval for Iomab-B

* Actinium- Iomab-B U.S. pivotal phase 3 Sierra trial design, primary endpoint, planned statistical analysis acceptable for marketing authorization application Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below